Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation Study of the Prediction of the Response to Second-line Hormone Therapy by 16α- [18F] Fluoro-17β-estradiol (FES) PET in Patients With Metastatic Breast Cancer

NCT03442504 is registered in ClinicalTrials.gov with Institut Cancerologie de l'Ouest as lead sponsor.

NCT NCT03442504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03442504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation Study of the Prediction of the Response to Second-line Hormone Therapy by 16α- [18F] Fluoro-17β-estradiol (FES) PET in Patients With Metastatic Breast Cancer
Lead sponsor
Institut Cancerologie de l'Ouest
Phase
Not applicable
Overall status
Unknown status
Start date
March 15, 2017
Completion date
June 30, 2024
Enrollment
57 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer